As colostrum launches into the mainstream, PanTheryx’s state-of-the-art facility will supply high-quality colostrum from dairy cows for a growing range of applications.
PHOENIX–(BUSINESS WIRE)–PanTheryx, a medical nutrition company focused on improving global health, has unveiled its newly expanded 112,000 sq. ft. production facility in Phoenix. With its $5 million investment, PanTheryx has doubled the company’s production capacity to meet the growing global demand for colostrum. New proprietary equipment and processing will provide unparalleled precision to ensure the standardization of bioactive profiles and overall quality, helping the company define the industry standard for high-quality bovine colostrum powder and finished products.
“Colostrum has a remarkable range of applications for improving human and animal health,” said Mark Braman, CEO of PanTheryx. “Our expanded facility will be able to meet and better serve our growing business and the needs of our customers by providing a consistent, reliable source of high-quality colostrum.”
Bovine colostrum — the first pre-milk from cows — is rich in nutrients, immune factors, and protective proteins that provide a powerful bioactive backbone for nutritional-based interventions and for building the next generation of innovative health and wellness products. While colostrum has been used for thousands of years as a traditional or complementary therapy, twenty-first century research is illuminating the science behind it. “What is different about colostrum as a nutritional intervention is that we have the evidence to show it works through a whole series of randomized clinical trials,” said Dr. Raymond Playford, Professor of Medicine at the University of Plymouth, and a PanTheryx Scientific Advisor. “These findings are further backed up by preclinical studies that allow us to understand the molecular processes involved.”
The findings, in turn, are bearing out in exciting new ways. “Colostrum has a potentially broad range of practical applications, from functional foods to new medicines,” said Dr. Mark Grabowsky, Chief Medical Officer at PanTheryx. “One of these areas is in global health, where colostrum-based products have the potential to address some of the most challenging, seemingly intractable public health issues.”
Key to promoting wider spread adoption of colostrum-based products is addressing the lack of standardization in a natural product with transitioning characteristics. “There are over 3,000 studies in bovine colostrum, but not all of them show consistent findings,” said Braman. “We believe some of the discrepancies can be attributed to differences in the quality and bioactive profile of the colostrum used. With our newly expanded Phoenix facility, we will be able to consistently deliver the same colostrum with high-throughput, year-round processing, and establish standards across the industry for the constant supply of the highest quality colostrum.”
PanTheryx is a medical nutrition company committed to realizing the potential of nutrition-based interventions to address a wide range of serious GI microbiome related health conditions. Our mission includes ensuring that the most at-risk populations have access to the benefits of our products. The company is headquartered in Boulder, CO, with production facilities in Phoenix, AZ and Ripon, CA.
For more information, please visit www.pantheryx.com.
Jessica Teilborg, 303-951-6883